SCHEMBL26324974

SCHEMBL26324974

Cc1cc(C)cc(N(c2ccc(Oc3ccccc3)cc2)C(C(=O)OC(C)C)C(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.39
ALOX5 P09917 1/20 0.38
NPY5R Q15761 3/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36
MMP16 P51512 1/20 0.36
ADAM17 P78536 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ACACB O00763 2/20 0.36
ACACA Q13085 2/20 0.36
MEN1 O00255 1/20 0.36
CYP2D6 P10635 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26324995 0.91 PTGS1 (0.42) PTGS1ALOX5NPY5RMMP1MMP2
SCHEMBL26324957 0.90 PTGS1 (0.41) PTGS1ALOX5NPY5RMMP1MMP2
SCHEMBL20564588 0.88 ALOX5 (0.41) PTGS1ALOX5NPY5RHSD17B1HSD17B2
SCHEMBL26324981 0.83 MEN1 (0.38) SMN1; SMN2MEN1KMT2ALMNAMAPK1
SCHEMBL26324940 0.82 TRPM8 (0.39) MMP2MMP9MMP8MMP13SMN1; SMN2
SCHEMBL26324980 0.81 PDCD1 (0.39) HSD17B1HSD17B2MMP1MMP2MMP3
SCHEMBL26324800 0.80 TSHR (0.42) MMP2MMP3MMP9MMP8MMP13
SCHEMBL26324999 0.79 ALOX5 (0.37) ALOX5MEN1KMT2ALMNAHTT
SCHEMBL25439886 0.78 ALOX5 (0.45) PTGS1ALOX5NPY5RSMN1; SMN2ACACB
SCHEMBL26325014 0.78 PDCD1 (0.51) MMP1MMP2MMP3MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767291-B2 Preparation of secondary amines with electrophilic N-linchpin reagents WILLIAM MARSH RICE UNIVERSITY (US) 2023-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767291-B2 Preparation of secondary amines with electrophilic N-linchpin reagents PNMT, NCL, NPM1 PTGS1 4470/4885ALOX5 2561/4885NPY5R 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.